BRPI0922288A2 - anticorpos monoclonais anti-ferroportina 1 e seus usos. - Google Patents

anticorpos monoclonais anti-ferroportina 1 e seus usos.

Info

Publication number
BRPI0922288A2
BRPI0922288A2 BRPI0922288A BRPI0922288A BRPI0922288A2 BR PI0922288 A2 BRPI0922288 A2 BR PI0922288A2 BR PI0922288 A BRPI0922288 A BR PI0922288A BR PI0922288 A BRPI0922288 A BR PI0922288A BR PI0922288 A2 BRPI0922288 A2 BR PI0922288A2
Authority
BR
Brazil
Prior art keywords
ferroportin
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
BRPI0922288A
Other languages
English (en)
Inventor
Ryan Witcher Derrick
Doen Mun Leung Donmienne
Vincent Manetta Joseph
Luan Peng
Tang Ying
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0922288A2 publication Critical patent/BRPI0922288A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0922288A 2008-12-05 2009-12-01 anticorpos monoclonais anti-ferroportina 1 e seus usos. BRPI0922288A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US23981809P 2009-09-04 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0922288A2 true BRPI0922288A2 (pt) 2018-08-28

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922288A BRPI0922288A2 (pt) 2008-12-05 2009-12-01 anticorpos monoclonais anti-ferroportina 1 e seus usos.

Country Status (25)

Country Link
EP (1) EP2373335B1 (pt)
JP (1) JP5713917B2 (pt)
KR (1) KR101353117B1 (pt)
CN (1) CN102238962B (pt)
AR (1) AR074398A1 (pt)
AU (1) AU2009322587B2 (pt)
BR (1) BRPI0922288A2 (pt)
CA (1) CA2745618C (pt)
CY (1) CY1117355T1 (pt)
DK (1) DK2373335T3 (pt)
EA (1) EA020472B1 (pt)
ES (1) ES2566343T3 (pt)
HR (1) HRP20160302T1 (pt)
HU (1) HUE028585T2 (pt)
IL (1) IL212731A0 (pt)
MX (1) MX2011005939A (pt)
NZ (1) NZ592545A (pt)
PA (1) PA8849601A1 (pt)
PL (1) PL2373335T3 (pt)
SG (1) SG171960A1 (pt)
SI (1) SI2373335T1 (pt)
TW (1) TW201023891A (pt)
UA (1) UA104741C2 (pt)
WO (1) WO2010065496A1 (pt)
ZA (1) ZA201103941B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027905A2 (pt) * 2012-05-14 2017-06-27 Genentech Inc anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use

Also Published As

Publication number Publication date
WO2010065496A1 (en) 2010-06-10
AR074398A1 (es) 2011-01-12
JP2012510814A (ja) 2012-05-17
CA2745618C (en) 2014-06-10
JP5713917B2 (ja) 2015-05-07
CA2745618A1 (en) 2010-06-10
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
HUE028585T2 (en) 2016-12-28
HK1158977A1 (zh) 2012-07-27
KR20110084996A (ko) 2011-07-26
UA104741C2 (uk) 2014-03-11
AU2009322587B2 (en) 2013-09-26
CN102238962A (zh) 2011-11-09
SG171960A1 (en) 2011-07-28
KR101353117B1 (ko) 2014-02-17
EP2373335A1 (en) 2011-10-12
MX2011005939A (es) 2011-06-27
IL212731A0 (en) 2011-07-31
TW201023891A (en) 2010-07-01
PL2373335T3 (pl) 2016-08-31
SI2373335T1 (sl) 2016-04-29
HRP20160302T1 (hr) 2016-04-22
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
ES2566343T3 (es) 2016-04-12
DK2373335T3 (en) 2016-05-02
CN102238962B (zh) 2014-02-12
ZA201103941B (en) 2012-11-28
PA8849601A1 (es) 2010-07-27
EP2373335B1 (en) 2016-02-24
CY1117355T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
CY2025024I2 (el) Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων
LTC2474557I2 (lt) Anti-cd79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
BRPI0815983A2 (pt) anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0906498A2 (pt) Anticorpo ron e seus usos
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
BRPI0812005A2 (pt) anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos
BRPI0923231A2 (pt) anticorpo anti-cmet.
BRPI0809677A2 (pt) Anticorpos anti-ige
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
HRP20150176T1 (xx) Protutijela protiv miostatina
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
IL207184B (en) Cysteine engineered anti-cd79b antibodies and antibody-drug conjugates
NO344963B1 (no) Humanisert antistoff

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.